DDInter894 DDInter1676
Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Hydroxyurea {u} (Compound) resembles {v} (Compound) Acetohydroxamic acid
Hydroxyurea {u} (Compound) treats {v} (Disease) hematologic cancer
Hydroxyurea {u} (Compound) binds {v} (Gene) CYP2D6
Hydroxyurea {u} (Compound) is included by {v} (Pharmacologic Class) Urea
Hydroxyurea {u} (Compound) causes {v} (Side Effect) Infestation NOS
Hydroxyurea {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Hydroxyurea {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentostatin
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Hydroxyurea {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Hydroxyurea (Compound) resembles Acetohydroxamic acid (Compound)
Hydroxyurea (Compound) treats hematologic cancer (Disease)
Hydroxyurea (Compound) binds CYP2D6 (Gene)
Hydroxyurea (Compound) is included by Urea (Pharmacologic Class)
Hydroxyurea (Compound) causes Infestation NOS (Side Effect)
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Hydroxyurea may lead to a major life threatening interaction when taken with Leflunomide